Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Postoperative Delirium

In brief

Neurosurgery is a risk factor for delirium. Dexmedetomidine might reduce delirium by reducing neuroinflammation, improving postoperative analgesia and sleep quality. The the primary hypothesis is that perioperative administration of dexmedetomidine can reduce the incidence of postoperative delirium

Key facts

Study ID

NCT06164314

Run by

Beijing Tiantan Hospital

People needed

366

Starts

2024-01-25

Expected to finish

2026-09-30

Last updated by the study team

2025-02-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with temporal glioma scheduled for a elective craniotomy
• Age ≥18 years
• Obtain written informed consent.

You may not qualify if…

• Patients with severe preoperative cognitive impairment
• History of traumatic brain injury or previous neurosurgery
• History of psychotropic medications
• Allergy to dexmedetomidine
• Pregnant or lactating women
• History of obstructive sleep apnoea syndrome
• Severe bradycardia(heart rate <40 beats/min), sick sinus syndrome or second-to-third degree atrioventricular block
• Severe hepatic dysfunction
• Severe renal dysfunction

Where it is running

• Beijing Tiantan Hospital — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.